Avid Bioservices Capabilities Update September 2026: ADC

Choosing the right CDMO can significantly influence the speed, quality, and success of a biologics program. In this webinar, Rich Richiri of Avid Bioservices explains how an integrated development and manufacturing strategy can help reduce risk while accelerating timelines from early development through commercial supply. He explores the benefits of standardized platforms, matched equipment across scales, and single-use manufacturing systems designed to streamline technology transfer and minimize operational surprises.

The discussion highlights capabilities spanning cell line development, process and analytical development, GMP manufacturing, and commercial production for a wide range of biologic modalities, including monoclonal antibodies, fusion proteins, enzymes, cytokines, and ADC intermediates. Attendees will also gain insight into approaches for achieving rapid DNA-to-clinic timelines, maintaining regulatory readiness, and ensuring reliable supply through strong quality systems, operational consistency, and collaborative client partnerships.

Watch the full webinar to learn how integrated biologics manufacturing strategies can accelerate development while supporting long-term commercial success.